585 results match your criteria: "Urticaria Cholinergic"
Comparative Efficacy of Mometasone Nasal Spray Combined with Different Doses of Desloratadine, and Montelukast in Childhood Allergic Rhinitis: A Randomized Clinical Trial.
Iran J Allergy Asthma Immunol
July 2024
Division of Allergy and Clinical Immunology, Department of Pediatrics, Bahrami Children's Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- Allergic rhinitis is a common issue in children, and while several medications like nasal corticosteroids and antihistamines are used to treat it, there's ongoing debate about the best dosage and combinations for maximum effectiveness.* -
- A study involving 64 children compared the effects of different drug combinations alongside mometasone furoate nasal spray, measuring symptoms like nasal congestion and sneezing.* -
- Results showed that using desloratadine twice daily or a combination of desloratadine and montelukast significantly improved symptom control compared to other treatment options.*
Key differences between chronic inducible and spontaneous urticaria.
Front Allergy
October 2024
Division of Allergy, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.
Introduction: The latest international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for urticaria recommends limited laboratory testing for chronic spontaneous urticaria (CSU) and selective testing for only certain chronic inducible urticaria (CIndU) subtypes, though the rationale for these recommendations is poorly explained. This study aimed to improve the understanding of CIndU subtypes by comprehensively comparing their demographic, clinical, and laboratory characteristics with those of the better-characterized CSU.
Methods: We conducted a retrospective analysis of 567 patients (median age 41 years, 67% female) diagnosed with CSU, symptomatic dermographism (SD), cold urticaria (ColdU), cholinergic urticaria (CholU), and delayed pressure urticaria (DPU).
Decoding the variability in clinical and laboratory profiles of Chronic Inducible Urticaria vs. Chronic Spontaneous Urticaria - a retrospective study from a tertiary care center.
Arch Dermatol Res
October 2024
Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Sector12, Chandigarh, 160012, India.
Article Synopsis
- Chronic inducible urticaria (CIndU) lasts longer than 6 weeks and is triggered by specific factors, but research on its severity and treatment is limited compared to chronic spontaneous urticaria (CSU).
- A study reviewed data from 222 CIndU patients and 226 CSU controls, finding that both groups were similar in age and gender, but CIndU patients had significantly lower CRP levels and a poorer quality of life score (CU-QOL).
- CIndU patients required more frequent antihistamine adjustments (80% vs. 52% in CSU) and took longer to achieve remission, averaging 60 days compared to 27.77 days for CSU patients.
Validation of the Cholinergic Urticaria Activity Score (CholUAS).
J Allergy Clin Immunol Pract
October 2024
Institute for Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany; Department of Dermatology and Allergology, Comprehensive Allergy Center, Kepler University Hospital, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria. Electronic address:
Background: In cholinergic urticaria (CholU), itchy wheal and flare-type skin reactions are triggered by sweat-inducing activities. The CholU activity score (CholUAS) is used to assess disease activity but has not yet been validated. The aim of the study was to validate the CholUAS, develop an English version, and provide instructions for scoring.
View Article and Find Full Text PDFUnraveling the causative connection between urticaria, inflammatory cytokines, and mental disorders: Perspectives from genetic evidence.
Skin Res Technol
September 2024
Development and Regeneration Key Laboratory of Sichuan Province, Institute of Neuroscience, Department of Pathology and Pathophysiology, Chengdu Medical College, Chengdu, China.
Article Synopsis
- The study investigates the link between urticaria (a skin condition) and mental disorders, confirming that individuals with urticaria are at a higher risk for conditions like ADHD and schizophrenia.
- Using data from various genome studies, researchers found that different types of urticaria are associated with specific mental health risks and examined the role of inflammatory cytokines.
- The findings suggest that inflammatory cytokines do not mediate the relationship between urticaria and mental disorders, indicating a need for integrated treatment approaches that consider both physical and mental health.
Chronic Urticaria in Children: A Single-Center Retrospective Study From Turkey.
Clin Pediatr (Phila)
September 2024
Department of Dermatology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Article Synopsis
- - The study aimed to explore the causes and characteristics of chronic urticaria (CU) in children under 18, finding that a majority of participants were aged 12 or older.
- - Chronic spontaneous urticaria (CSU) was the most common type, affecting 75% of the participants, while 18.5% also experienced angioedema; however, 56.5% had no identifiable cause for their urticaria.
- - Infections were the main identified trigger, accounting for 29.8%, with dental issues being the most common infection related to CU; the prevalence of chronic urticaria increased with age among the children studied.
Skin reaction patterns in cholinergic urticaria.
Allergol Int
September 2024
Department of Dermatology and Venerology, Kepler University Hospital, Linz, Austria; Johannes Kepler University, Center for Medical Research (ZMF), Linz, Austria; Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany. Electronic address:
Article Synopsis
- Cholingeric urticaria (CholU) involves varying skin reactions among patients, but these patterns are not well-defined or studied in terms of their impact.
- A study identified six distinct types of CholU skin reactions, with most patients (94%) showing at least one type, while sweating issues were especially pronounced in those with certain types (like Type VI).
- Type V reactions were found to correlate with the most severe disease presentation and highest quality of life impairment, indicating that different skin signs may reflect varying clinical features in CholU patients.
Severe cholinergic urticaria: Clinical characteristics and therapeutic approach.
Ann Dermatol Venereol
September 2024
Sorbonne University, Dermatology and Allergy Department, Tenon Hospital, UCARE and ACARE Tenon Hospital center Paris, France.
Combining dipyridamole and cilostazol with up-dosing antihistamines improves outcomes in chronic spontaneous urticaria with high D-dimer levels: A randomized controlled trial.
Exp Dermatol
August 2024
Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Article Synopsis
- * Patients were split into two groups: one received both antiplatelet therapy (cilostazol and dipyridamole) and antihistamine, while the other group only received antihistamine for four weeks.
- * Results showed that the antiplatelet group had a significantly greater reduction in Urticaria Activity Scores, improved quality of life, and decreased D-dimer levels, suggesting the combination treatment is more effective for certain CSU patients.
Case Report: Hives and faints, an unusual affair.
F1000Res
July 2024
Pathology, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, 442001, India.
Article Synopsis
- Cholinergic urticaria (CholU) is a rare skin condition that causes itchy hives triggered by sweating from activities like exercise, typically lasting 15-20 minutes.
- A 42-year-old male experienced unusual symptoms of syncope (fainting) alongside CholU, leading to a comprehensive evaluation to rule out other medical causes.
- His diagnosis was supported by increased IgE antibody levels, and treatment included nonsedating antihistamines along with health education about CholU.
New insights into chronic inducible urticaria.
Curr Allergy Asthma Rep
August 2024
Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, 10178, Berlin, Germany.
Article Synopsis
- Chronic inducible urticaria (CIndU) is a difficult-to-manage condition marked by recurring hives and swelling, triggered by specific factors, and recent research has focused on understanding its causes and improving treatment options.
- New methods for evaluating patient experiences have been developed, highlighting the significant impact CIndU has on quality of life and enabling better diagnosis through provocation tests for different subtypes.
- Currently, second-generation non-sedating antihistamines are the primary recommended treatment, but they often fall short; however, off-label use of omalizumab shows promise, along with other emerging therapies being researched for future options.
Article Synopsis
- Cholinergic urticaria with hypohidrosis or anhidrosis (CUHA) causes symptoms like itching, tingling, and reduced sweating, negatively impacting quality of life.
- Current treatments include antihistamines, steroids, and therapies to promote sweating, but the effectiveness of hot baths specifically needed assessment.
- In a study with eight CUHA patients, hot baths improved symptoms for around half of the participants, suggesting it could be a viable treatment option without severe side effects.
Chronic Inducible Urticaria.
Immunol Allergy Clin North Am
August 2024
Department of Dermatology and Venerology, Kepler University Hospital, Urticaria Center of Excellence and Reference (UCARE), Linz, Austria; Center for medical research, Johannes Kepler University, Linz, Austria; Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany. Electronic address:
Article Synopsis
- * Diagnosis relies on patient history, trigger tests, and self-reported symptoms.
- * Current treatments mirror those for chronic spontaneous urticaria but are largely off-label; new targeted therapies are in clinical trials due to the significant impact on patients.
Unveiling Treatment Response Predictors in Predominant Subtypes of Chronic Inducible Urticaria.
Int Arch Allergy Immunol
November 2024
Department of Dermatology, Koc University School of Medicine, Istanbul, Turkey.
Article Synopsis
- * A study involving 423 patients found that treatment response rates to antihistamines (AH) and omalizumab were generally higher in CIndU than in other chronic urticaria types, especially for symptomatic dermographism (SD) and cold urticaria.
- * Factors such as longer disease duration, presence of angioedema, and lower baseline urticaria control scores can help predict how well patients with CIndU will respond to antihistamine treatment.
Clozapine-induced cholinergic urticaria: a case report.
Ther Adv Psychopharmacol
May 2024
Établissement public de santé mentale de Ville Evrard, France.
Article Synopsis
- - Clozapine is effective for treatment-resistant schizophrenia but carries serious side effects like hematological issues and myocarditis, alongside less severe but impactful dermatological reactions.
- - A 25-year-old male experienced cholinergic urticaria—intense itching and redness triggered by sweating—after four months on clozapine, which impaired his daily life despite treatment adjustments.
- - Switching from clozapine to quetiapine resulted in improvement, highlighting the need for personalized treatment plans and the importance of managing side effects, even those that appear after an extended period.
Altered Sweat Composition Due to Changes in Tight Junction Expression of Sweat Glands in Cholinergic Urticaria Patients.
Int J Mol Sci
April 2024
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, 12203 Berlin, Germany.
Article Synopsis
- * Skin biopsies from CholU patients showed a decrease in local sweating, but total sweat volume remained the same, and specific tight junction proteins in sweat glands exhibited abnormal distribution.
- * A new ex vivo skin model has been developed to study sweat secretion in CholU patients, aiming to better understand the mechanisms behind this condition.
Acetylcholinesterase is regulated by exposure of ultraviolet B in skin keratinocytes: A potential inducer of cholinergic urticaria.
FASEB J
May 2024
Division of Life Science and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Hong Kong, China.
Article Synopsis
- - Cholinergic urticaria is a skin condition marked by red patches and hives that arise from triggers like exercise, sweating, and stress, potentially due to decreased levels of the enzyme acetylcholinesterase (AChE).
- - This decrease in AChE leads to excess acetylcholine (ACh) leaking into the skin, causing mast cells to release histamine and trigger inflammatory responses.
- - Research shows that exposure to ultraviolet B (UVB) light lowers AChE levels in skin cells by promoting specific micro-RNAs (miR-132 and miR-212), suggesting that UVB exposure plays a role in worsening cholinergic urticaria.
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
Zhonghua Jie He He Hu Xi Za Zhi
February 2024
Article Synopsis
- The methacholine challenge test (MCT) is a key method for assessing airway hyperresponsiveness, particularly for diagnosing and treating bronchial asthma.
- A consensus group of experts in respiratory health has updated guidelines on MCT usage, focusing on common clinical issues, preparation, safety, and result interpretation.
- The updated guidelines specify who should undergo the MCT, outline absolute contraindications, and aim to assist healthcare practitioners in effectively using the test for patient assessment and treatment decisions.
Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
Br J Dermatol
May 2024
Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany.
Article Synopsis
- Cholinergic urticaria (CholU) is a common condition where symptoms like itchy hives arise from sweating, but existing treatments often fail to provide adequate control for patients.
- In a phase IIa trial, the new oral medication izuforant was tested on adults with CholU who didn't respond well to traditional antihistamines.
- Results showed that while izuforant did not significantly improve the primary measures of urticaria activity, it did lead to noticeable improvements in patient-reported severity assessments compared to placebo.
A comparative analysis of chronic inducible urticaria in 423 patients: Clinical and laboratory features and comorbid conditions.
J Eur Acad Dermatol Venereol
March 2024
Department of Dermatology, Koc University School of Medicine, Istanbul, Turkey.
Article Synopsis
- * A study analyzed 423 CIndU patients, revealing that most were isolated CIndU, with symptomatic dermographism (SD) being the most common subtype, followed by cold urticaria (ColdU) and cholinergic urticaria (ChoU).
- * Findings indicate that patients with CSU plus CIndU are generally older, experience more severe symptoms, and have additional comorbid conditions compared to those with isolated CIndU, highlighting the differences in severity and characteristics
General anesthetic management in two patients with an anaphylaxis history cholinergic urticaria.
JA Clin Rep
August 2023
Department of Anesthesiology, Kumamoto City Hospital, 4-1-60, Higashimachi, Higashi-Ku, Kumamoto City, Kumamoto, 862-8505, Japan.
Article Synopsis
- Cholinergic urticaria is a condition where increased body temperature from activities like exercise or stress triggers hives and can lead to anaphylaxis.
- Two cases are reported where patients with a history of this condition underwent surgery, emphasizing the need for specific anesthetic management.
- The anesthetic strategy involved avoiding methods that could increase body temperature during surgery and using preventive medications to reduce stress and potential allergic reactions.
Chronic Urticaria and Angioedema: Masqueraders and Misdiagnoses.
J Allergy Clin Immunol Pract
August 2023
Department of Dermatology, Mayo Clinic, Rochester, Minn. Electronic address:
Article Synopsis
- Chronic urticaria is an itchy skin condition that lasts for at least 6 weeks, with both spontaneous cases (no clear triggers) and inducible cases (specific triggers like heat or cold).
- Angioedema is another condition that involves swelling beneath the skin, often occurring alongside chronic urticaria, but it lasts longer and can have different causes.
- Accurate diagnosis is crucial since chronic urticaria and angioedema can be confused with other conditions, impacting treatment and outcomes for patients.
Successful desensitization protocol for pyridostigmine in a 12 year old patient with myasthenia gravis.
Turk J Pediatr
May 2023
Department of Pediatric Allergy and Immunology, İnönü University Faculty of Medicine, Malatya, Türkiye.
Article Synopsis
- Myasthenia gravis is a chronic autoimmune condition that causes muscle weakness, and pyridostigmine bromide is commonly used to help manage its symptoms.
- A 12-year-old girl experienced urticaria (hives) as an allergic reaction to pyridostigmine bromide, which is rare in children.
- The report details a successful desensitization process that allowed the patient to continue using pyridostigmine without further reactions.
Comparative Safety Profiles of Individual Second-Generation H1-Antihistamines for the Treatment of Chronic Urticaria: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
J Allergy Clin Immunol Pract
August 2023
Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand; Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. Electronic address:
Article Synopsis
- The study investigates the safety profiles and dosing regimens of second-generation H1-antihistamines in patients with chronic urticaria, as existing information is lacking.
- A systematic review and network meta-analysis of 51 trials involving 7502 patients were conducted to evaluate safety outcomes like treatment discontinuation and adverse events.
- Results indicated that while variations existed in treatment tolerability and side effects, emedastine, mizolastine, and cetirizine had the least favorable safety profiles, particularly concerning CNS side effects.*
Severe atopic dermatitis improved with identification and targeted therapy of cholinergic urticaria.
Ann Allergy Asthma Immunol
May 2023
Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: